Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Pulse Biosciences ( (PLSE) ).
Pulse Biosciences, Inc. appointed Mr. Steven T. Weber as Vice President of Accounting and Global Corporate Controller on July 14, 2025. Mr. Weber, with over 25 years of finance experience, previously held senior roles at IGM Biosciences and Aeglea Biotherapeutics. His appointment includes a stock option plan tied to the company’s market capitalization milestones, reflecting a strategic move to align executive incentives with company growth targets.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Average Trading Volume: 174,133
Technical Sentiment Signal: Buy
Current Market Cap: $1.08B
See more insights into PLSE stock on TipRanks’ Stock Analysis page.